Both ABA and PPARγ agonists have previously been reported to ameliorate memory performance in Alzheimer’s disease (59, 90, 91) and dietary ABA has been shown to upregulate PPARγ in immune cells and thereby reduce the severity of inflammatory bowel disease and type 2 diabetes in mice (47, 58). This evidence concerns the gene PPARG and early-onset autosomal dominant Alzheimer disease.